Drugs / Socazolimab
Trials 11 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT04608786 | Feb 2021 → Dec 2022 | biliary tract cancer | Lee's Pharmaceutical Limited | Unknown | No outcome recorded |
| Phase 1 | NCT04603846 | Sep 2020 → Oct 2022 | urothelial carcinoma | Lee's Pharmaceutical Limited | Unknown | No outcome recorded |
| Phase 1 | NCT04346914 | Mar 2020 → Oct 2022 | small cell lung carcinoma | Lee's Pharmaceutical Limited | Unknown | No outcome recorded |
| Phase 1 | NCT03676959 | Aug 2018 → May 2022 | cervical cancer | Lee's Pharmaceutical Limited | Unknown | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT04849260 | Aug 2021 → May 2022 | metastatic melanoma | Lee's Pharmaceutical Limited | Unknown | No outcome recorded |
| Phase 1/2 | NCT04460066 | Nov 2020 → Dec 2021 | esophageal squamous cell carcinoma | Lee's Pharmaceutical Limited | Unknown | No outcome recorded |
| Phase 1/2 | NCT03676985 | Oct 2018 → Feb 2020 | osteosarcoma | Lee's Pharmaceutical Limited | Unknown | No outcome recorded |
| Phase 1/2 | NCT03676946 | Oct 2018 → Feb 2020 | urothelial carcinoma | Lee's Pharmaceutical Limited | Unknown | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT06459687 | Nov 2024 → Sep 2027 expected | cervical cancer | Lee's Pharmaceutical Limited | Recruiting | No outcome recorded |
| Phase 3 | NCT04878016 | Jul 2021 → Oct 2023 | small cell lung carcinoma | Lee's Pharmaceutical Limited | Completed | No outcome recorded |
| Phase 3 | NCT04359550 | Jun 2020 → Jun 2022 | osteosarcoma | Lee's Pharmaceutical Limited | Unknown | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | socazolimab | “investigating the safety, tolerability, and efficacy of the recombinant human anti-programmed death-ligand 1 monoclonal antibody socazolimab in combination with carboplatin and...” PMID 37020926 ↗ Feb 20233“Therefore, we assessed the safety and efficacy of the anti-PD-L1 monoclonal antibody Socazolimab in combination with nab-paclitaxel as first-line therapy in aUC (NCT04603846).” PMID 39418340 ↗ Feb 2025 “the neoadjuvant socazolimab, a novel PD-L1 inhibitor” PMID 36882775 ↗ Mar 2023 |
| Known as | Anti-PD-L1 SH1E2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802221 ↗ |
| Known as | SH1E2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802221 ↗ |
| Known as | STI-A1014 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802221 ↗ |
| Known as | ZKAB001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03676959 ↗ |
| Action | Inhibit | “Programmed cell death 1 ligand 1 inhibitor” CHEMBL4802221 ↗1“anti-PD-L1 monoclonal antibody” NCT04359550 ↗ |
| Modality | Monoclonal antibody | “a fully human monoclonal antibody targeting the Programmed Death - Ligand 1 (PD-L1) membrane receptor on T lymphocytes and other cells of the immune system” NCT03676946 ↗ |
| Route | Intravenous | “IV administration of ZKAB001” NCT03676946 ↗ |
| Target | CD274 | “Programmed cell death 1 ligand 1 inhibitor” CHEMBL4802221 ↗ |